$-0.69 EPS Expected for Aclaris Therapeutics, Inc. (ACRS)

Aclaris Therapeutics, Inc. (NASDAQ:ACRS) Logo

Analysts expect Aclaris Therapeutics, Inc. (NASDAQ:ACRS) to report $-0.69 EPS on November, 5.They anticipate $0.37 EPS change or 34.91 % from last quarter’s $-1.06 EPS. After having $-0.72 EPS previously, Aclaris Therapeutics, Inc.’s analysts see -4.17 % EPS growth. The stock increased 7.62% or $0.08 during the last trading session, reaching $1.13. About 779,546 shares traded. Aclaris Therapeutics, Inc. (NASDAQ:ACRS) has declined 92.35% since October 7, 2018 and is downtrending. It has underperformed by 92.35% the S&P500.

Aclaris Therapeutics, Inc., a clinical-stage biotechnology company, focuses on identifying, developing, and commercializing topical drugs to address various unmet needs in dermatology. The company has market cap of $45.41 million. The Company’s lead drug candidate is A-101, a hydrogen peroxide topical solution, which is in Phase III clinical trials for the treatment of seborrheic keratosis , a common non-malignant skin tumor. It currently has negative earnings. The firm is also developing A-101 as a prescription treatment for common warts.

More notable recent Aclaris Therapeutics, Inc. (NASDAQ:ACRS) news were published by: Globenewswire.com which released: “Aclaris Therapeutics Reports Second Quarter 2019 Financial Results, Provides Business Strategy Update and Provides Update on Clinical and Commercial Developments – GlobeNewswire” on August 08, 2019, also Finance.Yahoo.com with their article: “The Daily Biotech Pulse: Acceleron Shelves Muscular Dystrophy Drug Trial, Aclaris Aces Late-Stage Study – Yahoo Finance” published on September 17, 2019, Globenewswire.com published: “GTT Communications, Inc. (GTT), Sarepta Therapeutics, Inc. (SRPT) & Aclaris Therapeutics, Inc. (ACRS) – Class Action Alert – Bronstein, Gewirtz & Grossman, LLC – GlobeNewswire” on September 20, 2019. More interesting news about Aclaris Therapeutics, Inc. (NASDAQ:ACRS) were released by: Globenewswire.com and their article: “Aclaris Therapeutics to Announce First Quarter 2019 Financial Results on May 8, 2019 – GlobeNewswire” published on May 01, 2019 as well as Seekingalpha.com‘s news article titled: “AIM ImmunoTech leads healthcare gainers; Zynerba Pharmaceuticals leads the losers – Seeking Alpha” with publication date: September 19, 2019.

Aclaris Therapeutics, Inc. (NASDAQ:ACRS) Ratings Chart

Receive News & Ratings Via Email - Enter your email address below to receive a concise daily summary of the latest news and analysts' ratings with our FREE daily email newsletter.